



## Company Profile

Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as the AC5 Surgical Hemostatic Device™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures and is intended to be regulated as a medical device.

## Management Team

### Dr. Terrence W. Norchi

President, Chief Executive Officer and Director

### Richard E. Davis

Chief Financial Officer

## Recent News

Monday, October 01, 2018 - 07:00 AM

[Arch Therapeutics Announces 510\(k\) Submission to the U.S. FDA for AC5™ Topical Gel](#)

Tuesday, September 25, 2018 - 07:50 AM

[Arch Therapeutics to Provide Corporate Update at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018](#)

Wednesday, September 05, 2018 - 07:50 AM

[Arch Therapeutics Reports Topline Results from Skin Sensitization Study of AC5](#)

Tuesday, August 28, 2018 - 07:50 AM

[Arch Therapeutics to Provide Corporate Update at the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018](#)

Thursday, August 16, 2018 - 07:50 AM

[Arch Therapeutics Announces Poster Presentation at the 2018 Military Health System Research Symposium on Tuesday, August 21, 2018](#)

## DISCLAIMER


Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.

## Contact Information

### Arch Therapeutics, Inc.

235 Walnut Street  
Suite 6  
Framingham, MA 01702

## OTCQB: ARTH



Share Price	\$0.39
Volume	75.5k
Shares Outstanding	164,297,013
Market Cap	\$64.08m
52 Week High	\$0.80
52 Week Low	\$0.25

as of 11/16/2018